Daito Pharmaceutical Co.,Ltd.
4577.T · JPX
11/30/2025 | 8/31/2025 | 5/31/2025 | 2/28/2025 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.83 | 6.03 | 0.93 | 1.72 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 25.27 | 22.43 | 23.36 | 14.09 |
| Quality | ||||
| ROIC | 0.69% | 0.99% | 1.17% | 0.43% |
| Gross Margin | 18.19% | 19.66% | 16.12% | 16.61% |
| Cash Conversion Ratio | – | – | – | 3.17 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.06% | 3.94% | 3.19% | 2.21% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 100.00% |
| Safety | ||||
| Net Debt / EBITDA | 4.62 | 4.70 | 5.70 | 4.86 |
| Interest Coverage | 19.00 | 33.27 | 19.79 | 11.68 |
| Efficiency | ||||
| Inventory Turnover | 0.55 | 0.58 | 0.64 | 0.48 |
| Cash Conversion Cycle | 219.07 | 172.57 | 207.46 | 239.03 |